Zentexia

Programs


Zen-A 


Indication: Chronic wounds and surgical wounds


Regulatory Category: Topical Pharmaceutical


Chemistry: Small molecules optimized for topical application


Development stage: Preclinical


Lead candidate: ZN-2911


Pharmacodynamic profile: Confidential


Pharmacokinetic profile: Ideal compound solubility and distribution in the wound. Good penetration through relevant layers of the skin.

Zen-B (Owned by Vitexia ApS)


Indication: Dermatology (skin aging / senescence)


Regulatory Category: Topical dermocosmetic


Chemistry: Novel small molecules optimized for topical administration


Development stage: Preclinical


Lead candidate: Senectin D


Pharmacodynamic profile: Confidential


Pharmacokinetic profile: Optimized for topical administration with good penetration into deeper layers of the skin.


Zen-C


Indication: Osteoarthritis 


Regulatory Category: Systemic Pharmaceutical


Chemistry: Novel small molecules optimized for systemic administration


Development stage: Preclinical


Lead candidates: ZN-4262, ZN-4265, ZN-4269


Pharmacodynamic profile: Confidential


Pharmacokinetic profile: Optimized for oral administration. Good distribution to relevant peripheral tissues.